SecBot SecBot
8-K ·Filed May 5, 2026

DNTH

Dianthus Therapeutics, Inc. /DE/
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001690585-26-000021
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The early GO decision and Orphan Drug Designation materially de-risk claseprubart's clinical and regulatory path. Monitor for CAPTIVATE Part B top-line guidance by YE 2026 and Phase 3 gMG trial initiation in mid-2026 as the next major catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$90.42
T+0 close · May 5, 2026 · via day close
Latest settled
+18.25%
T+60 · $106.92
Vs SPY
+16.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $90.42entry
  2. T+1 · 6mo ago −5.47%α −5.14% · $85.47
  3. T+5 · 6mo ago −4.72%α −5.85% · $86.15
  4. T+20 · 6mo ago −6.03%α −8.81% · $84.97
  5. T+60 · 4mo ago +18.25%α +16.19% · $106.92

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeline progress: early GO decision in Phase 3 CAPTIVATE CIDP trial, FDA Orphan Drug Designation for claseprubart in myasthenia gravis, and selection of three initial indications for DNTH212. Cash of $1.2B provides runway into 2030, removing near-term financing risk.

Key Financial Metrics

EPS
−$0.85
Revenue
$463.0K
-60.2% YoY

Key Facts

  • Early GO decision reached in Phase 3 CAPTIVATE CIDP trial after 20 confirmed responders with <40 patients completing Part A.
  • Claseprubart granted FDA Orphan Drug Designation for myasthenia gravis.
  • Cash, cash equivalents and investments of $1.2B as of March 31, 2026, providing runway into 2030.
  • Closed upsized public offering with gross proceeds of ~$719 million on March 12, 2026.
  • Net loss for Q1 2026: $40.8M ($0.85/share) vs. $29.5M ($0.82/share) in Q1 2025.
  • Phase 2 MoMeNtum MMN trial top-line results on track for Q4 2026; Phase 3 EMERGE gMG trial to initiate mid-2026 with 2H 2028 top-line.
  • First three priority indications for DNTH212: Sjögren's Disease, SLE, Dermatomyositis.

Financial Impact

Q1 2026 net loss of $40.8M ($0.85/share) vs $29.5M ($0.82/share) in prior year; revenue of $463K (license) vs $1.163M. No financial guidance provided.

net losscash positionrevenue

Risk Factors

  • Clinical trial failure in upcoming Phase 3 or Phase 2 readouts.
  • Competition from approved complement inhibitors and other therapies.
  • Dilution from the March 2026 offering; ~48M shares outstanding post-offering.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001690585-26-000021
Document: dnth-20260505.htm0001690585-26-000021
Document: 0001690585-26-000021-index-headers.html0001690585-26-000021
Document: 0001690585-26-000021-index.html0001690585-26-000021
Document: 0001690585-26-000021.txt0001690585-26-000021
8-K Data (Synthetic)0001690585-26-000021

Track record

23 reports on DNTH

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026